We are live on ! Find out more
OSTX icon

OS Therapies

30 hedge funds and large institutions have $4.09M invested in OS Therapies in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

808% more capital inflows, than outflows

Capital inflows: $2.66M | Capital outflows: $292K

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

15% more funds holding

Funds holding: 26 → 30 (+4)

3.19% more ownership

Funds ownership: 5.05% → 8.23% (+3.2%)

Holders
30
Holders Change
+4
Holders Change %
+15.38%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
8
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OSTX Hedge Fund Activity: Q1 2026 in Review

30 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in OS Therapies (OSTX) for Q1 2026, worth a combined $4.09M — up 64% from $2.49M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new OSTX positions and 6 closed out — a net gain of 5 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $637K. The largest seller was Marshall Wace, exiting entirely with an estimated $154K sold.

  • 30 institutional investors held OS Therapies (OSTX) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $4.09M of OS Therapies stock for Q1 2026, up 64% quarter-over-quarter.
  • 11 funds opened new OS Therapies positions in Q1 2026 and 6 closed out, a net change of +5 holders.
  • The largest OS Therapies buyer in Q1 2026 was Susquehanna International Group, an estimated $637K added.
  • The largest OS Therapies seller in Q1 2026 was Marshall Wace, an estimated $154K sold.

Based on aggregated 13F filings for Q1 2026.